<DOC>
	<DOC>NCT00237887</DOC>
	<brief_summary>A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history. Subject had a clinical diagnosis of psoriasis for at least 6 months, had moderate to severe plaque psoriasis. Subject was able and willing to selfadminister sc injections or had available qualified person(s) to administer sc injections Subject had previously received antiTNF therapy. Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy Subject cannot avoid excessive sun exposure Subject is taking or requires oral or injectable corticosteroids Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study Female subject who is pregnant or breastfeeding or considering becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>adalimumab</keyword>
</DOC>